Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482020 | 0.91 | MAPK14 (0.80) | MAPK14POLBTHRBPDE1C | |
| SCHEMBL4379163 | 0.90 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4468220 | 0.90 | MAPK14 (0.78) | MAPK14MAPTLMNATP53RXFP1 | |
| SCHEMBL4467417 | 0.89 | MAPK14 (0.89) | MAPK14POLBTHRBPDE1C | |
| SCHEMBL4392919 | 0.89 | MAPK14 (0.89) | MAPK14MAPTPOLBTHRBPDE1C | |
| SCHEMBL4381283 | 0.88 | MAPK14 (0.79) | MAPK14MAPTLMNATP53RXFP1 | |
| SCHEMBL4488916 | 0.88 | MAPK14 (0.77) | MAPK14MAPTTHRB | |
| SCHEMBL4376522 | 0.86 | MAPK14 (0.72) | MAPK14MAPTLMNATP53RXFP1 | |
| SCHEMBL4477534 | 0.85 | MAPK14 (0.82) | MAPK14MAPTLMNATP53 | |
| SCHEMBL4382379 | 0.85 | MAPK14 (0.82) | MAPK14POLBTHRBPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAPK14 41/4885MAPT 2803/4885LRRK2 342/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885MAPT 2543/4885LRRK2 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.